Values and Preferences on the Use of Oral Pre-exposure Prophylaxis (PrEP) for HIV Prevention Among Multiple Populations: A Systematic Review of the Literature

Florence M Koechlin, Virginia A Fonner, Sarah L Dalglish, Kevin R O'Reilly, Rachel Baggaley, Robert M Grant, Michelle Rodolph, Ioannis Hodges-Mameletzis, Caitlin E Kennedy, Florence M Koechlin, Virginia A Fonner, Sarah L Dalglish, Kevin R O'Reilly, Rachel Baggaley, Robert M Grant, Michelle Rodolph, Ioannis Hodges-Mameletzis, Caitlin E Kennedy

Abstract

Daily oral pre-exposure prophylaxis (PrEP) is the use of antiretroviral drugs by HIV-negative people to prevent HIV infection. WHO released new guidelines in 2015 recommending PrEP for all populations at substantial risk of HIV infection. To prepare these guidelines, we conducted a systematic review of values and preferences among populations that might benefit from PrEP, women, heterosexual men, young women and adolescent girls, female sex workers, serodiscordant couples, transgender people and people who inject drugs, and among healthcare providers who may prescribe PrEP. A comprehensive search strategy reviewed three electronic databases of articles and HIV-related conference abstracts (January 1990-April 2015). Data abstraction used standardised forms to categorise by population groups and relevant themes. Of 3068 citations screened, 76 peer-reviewed articles and 28 conference abstracts were included. Geographic coverage was global. Most studies (N = 78) evaluated hypothetical use of PrEP, while 26 studies included individuals who actually took PrEP or placebo. Awareness of PrEP was low, but once participants were presented with information about PrEP, the majority said they would consider using it. Concerns about safety, side effects, cost and effectiveness were the most frequently cited barriers to use. There was little indication of risk compensation. Healthcare providers would consider prescribing PrEP, but need more information before doing so. Findings from a rapidly expanding evidence base suggest that the majority of populations most likely to benefit from PrEP feel positively towards it. These same populations would benefit from overcoming current implementation challenges with the shortest possible delay.

Keywords: HIV; HIV prevention; Multiple populations; Pre-exposure prophylaxis (PrEP); Systematic review; Tenofovir; Values and preferences.

Conflict of interest statement

Conflict of interest

All authors declare that they have no conflict of interest.

Human and Animal Participants

This article does not contain any studies with human participants or animals performed by the authors.

Figures

Fig. 1
Fig. 1
Disposition of citations through the search and screening process

References

    1. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–2599. doi: 10.1056/NEJMoa1011205.
    1. Fonner VA, Dalglish S, Kennedy CE, et al. Oral tenofovir-based HIV pre-exposure prophylaxis (PrEP) for all populations: a systematic review and meta-analysis of effectiveness, safety, behavioural, and reproductive health outcomes. AIDS. 2016;30(12):1973–1983. doi: 10.1097/QAD.0000000000001145.
    1. World Health Organization . Guidance on pre-exposure oral prophylaxis (PrEP) for serodiscordant couples, men and transgender women who have sex with men at high risk of HIV. Geneva: WHO; 2012.
    1. World Health Organization . Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations. Geneva: WHO; 2014.
    1. World Health Organization . Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Geneva: WHO; 2015.
    1. Arnold EA, Hazelton P, Lane T, et al. A qualitative study of provider thoughts on Implementing pre-exposure prophylaxis (PrEP) in clinical settings to prevent HIV infection. PLoS ONE. 2012;7(7):e40603. doi: 10.1371/journal.pone.0040603.
    1. Auerbach JD, Banyan A, Riordan M. Will and should women in the U.S. use PrEP? Findings from a focus group study of at-risk, HIV-negative women in Oakland, Memphis, San Diego and Washington, D.C. J Acquir Immune Defic Syndr. 2012;15:193.
    1. Auerbach JD, Kinsky S, Brown G, Charles V. Knowledge, attitudes, and likelihood of pre-exposure prophylaxis (PrEP) use among US women at risk of acquiring HIV. AIDS Patient Care STDs. 2015;29(2):102–110. doi: 10.1089/apc.2014.0142.
    1. Bekker L-G, Hughes J, Amico R, et al. HPTN 067/ADAPT Cape Town: a comparison of daily and nondaily PrEP dosing in African Women. Paper presented at: CROI 2015. Seattle, 2015 [Abstract no. 978LB].
    1. Brubaker SG, Darbes L, Bukusi E, Cohen CR. Theoretical acceptability of four interventions to reduce the risk of HIV transmission among HIV discordant couples trying to conceive. Rome: International AIDS Society; 2011.
    1. Castro JG, Jones DL, Weiss SM. STD patients’ preferences for HIV prevention strategies. HIV/AIDS (Auckland, NZ) 2014;6:171–175.
    1. Corneli A, Perry B, Agot K, Ahmed K, Malamatsho F, Van Damme L. Facilitators of adherence to the study pill in the FEM-PrEP clinical trial. PLoS ONE. 2015;10(4):e0125458. doi: 10.1371/journal.pone.0125458.
    1. Corneli A, Perry B, McKenna K, et al. Participants’ explanations for nonadherence in the FEM-PrEP clinical trial. J Acquir Immune Defic Syndr. 2016;71(4):452–461. doi: 10.1097/QAI.0000000000000880.
    1. Corneli AM, Agot K, Ahmed K, Olang’o L, Makatu S, Lombaard J, Malahleha M, Van Damme L, FEM-PrEP Study Group. The association between risk perception and adherence in the FEM-PrEP clinical trial. 7th IAS Conference on HIV Pathogenesis and Treatment. Kuala Lumpur, 2013 [Abstract no. MOLBPE28].
    1. Cunningham WE, Galea JT, Kinsler JJ, et al. The acceptability of pre-exposure prophylaxis (PrEP) for HIV prevention in Lima, Peru. AIDS 2008—17th International AIDS Conference. Mexico, 2008 [Abstract no. WEPE0260].
    1. Desai M, Gafos M, McCormack S, Nardone A. Healthcare workers knowledge of, attitudes to and practice of pre-exposure prophylaxis for HIV. HIV Med. 2014;15:28.
    1. Dunkle K, Wingood G, Camp C, DiClemente R. Intention to use pre-exposure prophylaxis among African-American and white women in the United States: results from a national telephone survey. Paper presented at: 17th International AIDS Conference. Mexico, 2008.
    1. Eisingerich AB, Wheelock A, Gomez GB, Garnett GP, Dybul MR, Piot PK. Attitudes and acceptance of oral and parenteral HIV preexposure prophylaxis among potential user groups: a multinational study. PLoS ONE. 2012;7(1):e28238. doi: 10.1371/journal.pone.0028238.
    1. Engeran-Cordova W. ea. Community survey indicates low viability of PrEP for HIV prevention. Paper presented at: XIX International AIDS Conference. Washington, 2012 [Abstract WEPE265].
    1. Escudero DJ, Kerr T, Wood E, et al. Acceptability of HIV pre-exposure prophylaxis (PrEP) among people who inject drugs (PWID) in a Canadian setting. AIDS Behav. 2014;19(5):752–757. doi: 10.1007/s10461-014-0867-z.
    1. Flash CA, Stone VE, Mitty J, Mimiaga M, Hall KT, Krakower D, Mayer KH. Acceptability of oral or vaginal HIV pre-exposure prophylaxis among at-risk black women in the United States. Paper presented at: XIX International AIDS Conference. Washington, 2012 [Abstract LBPE41—Poster Exhibition].
    1. Flash CA, Stone VE, Mitty JA, et al. Perspectives on HIV prevention among urban black women: a potential role for HIV pre-exposure prophylaxis. AIDS Patient Care STDS. 2014;28(12):635–642. doi: 10.1089/apc.2014.0003.
    1. Fowler N, Arkell P, Abouyannis M, James C, Roberts L. Attitudes of serodiscordant couples towards antiretroviral-based HIV prevention strategies in Kenya: a qualitative study. AIDS Patient Care STDs. 2015;29(1):33–42. doi: 10.1089/apc.2014.0210.
    1. Galea JT, Kinsler JJ, Salazar X, et al. Acceptability of pre-exposure prophylaxis as an HIV prevention strategy: barriers and facilitators to pre-exposure prophylaxis uptake among at-risk Peruvian populations. Int J STD AIDS. 2011;22(5):256–262. doi: 10.1258/ijsa.2009.009255.
    1. Galindo GR, Walker JJ, Hazelton P, et al. Community member perspectives from transgender women and men who have sex with men on pre-exposure prophylaxis as an HIV prevention strategy: implications for implementation. Implement Sci. 2012;7:116. doi: 10.1186/1748-5908-7-116.
    1. Gilleece Y, Whetham J, Charlwood L, McInnes C, Payne E, Taylor S. Pre-exposure prophylaxis exposure for conception as a risk-reduction strategy in HIV-positive men and HIV-negative women in the UK. HIV Med. 2011;12:10.
    1. Golub S, Lelutiu-Weinberger C, Gamarel K, Rendina J, Nanin J, Parsons J. Psychosocial predictors of acceptability and risk compensation for pre-exposure prophylaxis. (PrEP): results from 3 studies of critical populations. J Int Assoc Physician AIDS Care. 2012;11(6):394.
    1. Golub SA. Tensions between the epidemiology and psychology of HIV risk: implications for pre-exposure prophylaxis. AIDS Behav. 2014;18(9):1686–1693. doi: 10.1007/s10461-014-0770-7.
    1. Golub SA, Gamarel KE, Rendina HJ, Surace A, Lelutiu-Weinberger CL. From efficacy to effectiveness: facilitators and barriers to PrEP acceptability and motivations for adherence among MSM and transgender women in New York City. AIDS Patient Care STDS. 2013;27(4):248–254. doi: 10.1089/apc.2012.0419.
    1. Guest G, Shattuck D, Johnson L, et al. Acceptability of PrEP for HIV prevention among women at high risk for HIV. J Women’s Health . 2010;19(4):791–798. doi: 10.1089/jwh.2009.1576.
    1. Heffron R, Ngure K, Mugo N, et al. Willingness of Kenyan HIV-1 serodiscordant couples to use antiretroviral-based HIV-1 prevention strategies. J Acquir Immune Defic Syndr. 2012;61(1):116–119. doi: 10.1097/QAI.0b013e31825da73f.
    1. Idoko J, Folayan MO, Dadem NY, Kolawole GO, Anenih J, Alhassan E. “Why should I take drugs for your infection?”: outcomes of formative research on the use of HIV pre-exposure prophylaxis in Nigeria. BMC Public Health. 2015;15:349. doi: 10.1186/s12889-015-1690-9.
    1. Jackson T, Huang A, Chen H, Gao X, Zhang Y, Zhong X. Predictors of willingness to use HIV pre-exposure prophylaxis among female sex workers in Southwest China. AIDS Care. 2013;25(5):601–605. doi: 10.1080/09540121.2012.726341.
    1. Kandathil S, Champeau D. Women initiated solution to prevent HIV/AIDS (the WISH study): factors associated with intentions to use microbicides and tenofovir. Paper presented at: XIX International AIDS Conference. Washington, 2012 [Abstract WEPE268—Poster Exhibition].
    1. Kapur A, Tang E, Tieu H, Koblin B, Ellman T, Sobieszczyk M. Knowledge, attitudes and willingness of New York City providers to prescribe oral pre-exposure prophylaxis (PrEP) for HIV prevention. Paper presented at: XIX International AIDS Conference. Washington, 2012.
    1. Karris MY, Beekmann SE, Mehta SR, Anderson CM, Polgreen PM. Are we prepped for preexposure prophylaxis (PrEP)? provider opinions on the real-world use of PrEP in the United States and Canada. Clin Infect Dis. 2013;58(5):704–712. doi: 10.1093/cid/cit796.
    1. Khawcharoenporn T, Chunloy K, Apisarnthanarak A. HIV knowledge, risk perception and pre-exposure prophylaxis interest among Thai university students. Int J STD AIDS. 2015;26(14):1007–1016. doi: 10.1177/0956462414564607.
    1. Khawcharoenporn T, Kendrick S, Smith K. HIV risk perception and preexposure prophylaxis interest among a heterosexual population visiting a sexually transmitted infection clinic. AIDS Patient Care STDS. 2012;26(4):222–233.
    1. Krakower D, Ware N, Mitty JA, Maloney K, Mayer KH. HIV providers’ perceived barriers and facilitators to implementing pre-exposure prophylaxis in care settings: a qualitative study. AIDS Behav. 2014;18(9):1712–1721. doi: 10.1007/s10461-014-0839-3.
    1. Kruse L, Stover K, Henderson H. Perceptions of emtricitabine-tenofovir in HIV PrEP. HIV Clin. 2014;26(1):1–4.
    1. Kuo I, Gregory Phillips I, Magnus M, et al. Willingness to use pre-exposure prophylaxis among community-recruited injection drug users. Race/Ethnicity. 2014;50(228):82–87.
    1. Kwakwa H. Perceptions of HIV pre-exposure prophylaxis in a high-risk population in urban United States. Paper presented at: 2014 National STD Prevention Conference, Atlanta, 2014.
    1. Kwakwa H, Wahome R. Perceptions of HIV pre-exposure prophylaxis in African and caribbean communities in urban United States. Sex Transm Dis. 2014;41:S123–S124. doi: 10.1097/OLQ.0000000000000075.
    1. Leonardi M, Lee E, Tan DH. Awareness of, usage of and willingness to use HIV pre-exposure prophylaxis among men in downtown Toronto, Canada. Int J STD AIDS. 2011;22(12):738–741. doi: 10.1258/ijsa.2011.011057.
    1. Liu A, Cohen S, Follansbee S, et al. Early experiences implementing pre-exposure prophylaxis (PrEP) for HIV prevention in San Francisco. PLoS Med. 2014;11(3):e1001613. doi: 10.1371/journal.pmed.1001613.
    1. Mack N, Evens EM, Tolley EE, et al. The importance of choice in the rollout of ARV-based prevention to user groups in Kenya and South Africa: a qualitative study. J Int AIDS Soc. 2014;17(3 Suppl 2):19157.
    1. Mack N, Odhiambo J, Wong CM, Agot K. Barriers and facilitators to pre-exposure prophylaxis (PrEP) eligibility screening and ongoing HIV testing among target populations in Bondo and Rarieda, Kenya: results of a consultation with community stakeholders. BMC Health Serv Res. 2014;14(1):231. doi: 10.1186/1472-6963-14-231.
    1. Madenwald T, Fuchs J, Sobieszczyk M, et al. Attitudes and intent to use PrEP among current phase II preventive HIV-1 vaccine trial participants. Paper presented at: AIDS Research and Human Retroviruses. New York, 2011.
    1. Magazi B, Stadler J, Delany-Moretlwe S, et al. Influences on visit retention in clinical trials: insights from qualitative research during the VOICE trial in Johannesburg, South Africa. BMC Women’s Health. 2014;14:88. doi: 10.1186/1472-6874-14-88.
    1. Mark D, Amico K, Wallace M, et al. Acceptability of oral intermittent pre-exposure prophylaxis as a biomedical HIV prevention strategyresults from the South African ADAPT (HPTN 067) Preparatory Study. Paper presented at: Journal of the International AIDS Society. Geneva, 2012.
    1. Matthews LT, Heffron R, Mugo NR, et al. High medication adherence during periconception periods among HIV-1-uninfected women participating in a clinical trial of antiretroviral pre-exposure prophylaxis. J Acquir Immune Defic Syndr. 2014;67(1):91–97. doi: 10.1097/QAI.0000000000000246.
    1. Matyanga CMJ, Khoza S, Gavi S. HIV pre-exposure prophylaxis: pharmacists knowledge, perception and willingness to adopt future implementation in a Zimbabwean urban Setting. East and Cent African J Pharm Sci. 2014;17:3–9.
    1. Mbogua J, Ngongo B, Ndegwa J, Bender B, Manguyu F. A survey of community opinions and preferences on PrEP, microbicides and vaccines in 5 regions and with key populations in Kenya. Paper presented at: AIDS Research and Human Retroviruses. New York, 2013.
    1. McKenna KJ, Ahmed K, Agot K, Makatu SJ, Odhiambo J, Skhosana J, Stalker M, Corneli A, for the FEM-PrEP Study Group. Risk perception and HIV worry among seroconverters in the FEM-PrEP clinical trial. 7th IAS Conference on HIV Pathogenesis and Treatment. Kuala Lumpur, 2013 [Abstract no. TUPE3862013].
    1. Mijiti P, Yahepu D, Zhong X, et al. Awareness of and willingness to use oral pre-exposure prophylaxis for HIV prevention among HIV-serodiscordant heterosexual couples: a cross-sectional survey in Xinjiang, China. PLoS ONE. 2013;8(7):e67392. doi: 10.1371/journal.pone.0067392.
    1. Mills LA, Kwaro D, Odongo F, et al. Acceptability of novel ARV-based HIV prevention methods in a rural Kenyan health and demographic surveillance community. Paper presented at: AIDS 2012 Conference Poster. Washington, 2012 [Abstract THPE121].
    1. Minnis AM, Gandham S, Richardson BA, et al. Adherence and acceptability in MTN 001: a randomized cross-over trial of daily oral and topical tenofovir for HIV prevention in women. AIDS Behav. 2013;17(2):737–747. doi: 10.1007/s10461-012-0333-8.
    1. Montgomery ET, van der Straten A, Stadler J, et al. Male partner influence on women’s HIV prevention trial participation and use of pre-exposure prophylaxis: the importance of “understanding”. AIDS Behav. 2015;19(5):784–793. doi: 10.1007/s10461-014-0950-5.
    1. Mujugira A, Heffron R, Celum C, Mugo N, Nakku-Joloba E, Baeten JM. Fertility intentions and interest in early antiretroviral therapy among East African HIV-1-infected individuals in serodiscordant partnerships. J Acquir Immune Defic Syndr. 2013;63(1):e33–e35. doi: 10.1097/QAI.0b013e318288bb32.
    1. Mullins TL, Lally M, Zimet G, Kahn JA. Clinician attitudes toward CDC interim pre-exposure prophylaxis (PrEP) guidance and operationalizing PrEP for adolescents. AIDS Patient Care STDS. 2015;29(4):193–203. doi: 10.1089/apc.2014.0273.
    1. Ngure K, Baeten JM, Mugo N, et al. My intention was a child but I was very afraid: fertility intentions and HIV risk perceptions among HIV-serodiscordant couples experiencing pregnancy in Kenya. AIDS Care. 2014;26(10):1283–1287. doi: 10.1080/09540121.2014.911808.
    1. Nwagwu G, Georges J, Weathers N. Perceived barriers to adoption of pre-exposure HIB therapy among MfF-TG youths. Commun Nurs Res. 2013;46:471.
    1. Parker K. Evaluation of an individual-level intervention to increase knowledge and the likelihood of use for PrEP: results from a pilot study. Paper presented at: 2014 National STD Prevention Conference. Atlanta, 2014.
    1. Peinado J, Lama JR, Galea JT, et al. Acceptability of oral versus rectal HIV preexposure prophylaxis among men who have sex with men and transgender women in Peru. J Int Assoc Provid AIDS Care. 2013;12(4):278–283. doi: 10.1177/1545109712473650.
    1. Peng B, Yang X, Zhang Y, et al. Willingness to use pre-exposure prophylaxis for HIV prevention among female sex workers: a cross-sectional study in China. HIV/AIDS—Res Palliat Care. 2012;4:149–158. doi: 10.2147/HIV.S33445.
    1. Prem Kumar SG, Kumar GA, Poluru R, et al. Contact with HIV prevention programmes & willingness for new interventions among truckers in India. Indian J Med Res. 2013;137(6):1061–1071.
    1. Puro V, Palummieri A, De Carli G, Piselli P, Ippolito G. Attitude towards antiretroviral pre-exposure prophylaxis (PrEP) prescription among HIV specialists. BMC Infect Dis. 2013;13(1):217. doi: 10.1186/1471-2334-13-217.
    1. Qiu L, Tian K, Zhong X, et al. Investigation on acceptability of pre-exposure prophylaxis among female sex workers in Sichuan, Xinjiang and Guangxi of China. J Shanghai Jaiotong Univ. 2012;32(4):508–513.
    1. Roberts ST, Haberer J, Celum C, et al. Intimate partner violence and adherence to HIV pre-exposure prophylaxis (PrEP) in African women in HIV serodiscordant relationships: A prospective cohort study. J Acquir Immune Defic Syndr. 2016;73(3):313–322. doi: 10.1097/QAI.0000000000001093.
    1. Roberts ST, Heffron R, Ngure K, et al. Preferences for daily or intermittent pre-exposure prophylaxis regimens and ability to anticipate sex among HIV uninfected members of Kenyan HIV serodiscordant couples. AIDS Behav. 2014;18(9):1701–1711. doi: 10.1007/s10461-014-0804-1.
    1. Rosenthal E, Piroth L, Cua E, et al. Preexposure prophylaxis (PrEP) of HIV infection in France: a nationwide cross-sectional study (PREVIC study) AIDS Care. 2014;26(2):176–185. doi: 10.1080/09540121.2013.803014.
    1. Rubtsova A, Wingood G, Dunkle K, Camp C, DiClemente R. Young adult women and correlates of potential adoption of pre-exposure prophylaxis (PrEP): results of a national survey. Curr HIV Res. 2014;11(7):543–548. doi: 10.2174/1570162X12666140129104952.
    1. Scherer ML, Douglas NC, Churnet BH, et al. Survey of HIV care providers on management of HIV serodiscordant couples—assessment of attitudes, knowledge, and practices. AIDS Care. 2014;26(11):1435–1439. doi: 10.1080/09540121.2014.920950.
    1. Schneider JA, Dandona R, Pasupneti S, et al. Initial commitment to pre-exposure prophylaxis and circumcision for HIV prevention amongst Indian truck drivers. PLoS ONE. 2010;5(7):e11922. doi: 10.1371/journal.pone.0011922.
    1. Schneider JA, Kumar R, Dandona R, et al. Social network and risk-taking behavior most associated with rapid HIV testing, circumcision, and preexposure prophylaxis acceptability among high-risk Indian men. AIDS Patient Care STDs. 2012;26(10):631–640. doi: 10.1089/apc.2012.0188.
    1. Schwartz SR, Bassett J, Sanne I, Phofa R, Yende N, Van Rie A. Implementation of a safer conception service for HIV-affected couples in South Africa. AIDS. 2014;28(Suppl 3):S277–S285. doi: 10.1097/QAD.0000000000000330.
    1. Senn H, Wilton J, Sharma M, Fowler S, Tan DH. Knowledge of and opinions on HIV preexposure prophylaxis among front-line service providers at Canadian AIDS service organizations. AIDS Res Hum Retrovir. 2013;29(9):1183–1189.
    1. Shaeer KM, Sherman EM, Shafiq S, Hardigan P. Exploratory survey of Florida pharmacists’ experience, knowledge, and perception of HIV pre-exposure prophylaxis. J American Pharm Assoc. 2014;54(6):610–617. doi: 10.1331/JAPhA.2014.14014.
    1. Sharma M, Wilton J, Senn H, Fowler S, Tan DHS. Preparing for PrEP: perceptions and readiness of Canadian physicians for the implementation of HIV pre-exposure prophylaxis. PLoS ONE. 2014;9(8):e105283. doi: 10.1371/journal.pone.0105283.
    1. Smith DK, Ntekop E, Pals S. Willingness to use, prescribe, or publicly fund PrEP services: results from 3 national surveys in the United States. Paper presented at: AIDS 2010. Vienna, 2010.
    1. Smith DK, Toledo L, Smith DJ, Adams MA, Rothenberg R. Attitudes and program preferences of African-American urban young adults about pre-exposure prophylaxis (PrEP) AIDS Educ Prev. 2012;24(5):408–421. doi: 10.1521/aeap.2012.24.5.408.
    1. Socías ME, Sued O, Pryluka D, Fink V, Cesar C, Cahn P. Willingness of Argentinean HIV care providers to adopt PrEP as a risk reduction strategy in different scenarios. 7th IAS Conference on HIV Pathogenesis and Treatment. Kula Lumpur, 2013 [Abstract no. TUPE418].
    1. Spector AY, Remien RH, Tross S. PrEP in substance abuse treatment: a qualitative study of treatment provider perspectives. Subst Abuse Treat Prev Policy. 2015;10(1):1. doi: 10.1186/1747-597X-10-1.
    1. Stein M, Thurmond P, Bailey G. Willingness to use HIV pre-exposure prophylaxis among opiate users. AIDS Behav. 2014;18(9):1694–1700. doi: 10.1007/s10461-014-0778-z.
    1. Tang EC, Sobieszczyk ME, Shu E, Gonzales P, Sanchez J, Lama JR. Provider attitudes toward oral preexposure prophylaxis for HIV prevention among high-risk men who have sex with men in Lima, Peru. AIDS Res Hum Retrovir. 2014;30(5):416–424. doi: 10.1089/aid.2013.0212.
    1. Tangmunkongvorakul A, Chariyalertsak S, Amico KR, et al. Facilitators and barriers to medication adherence in an HIV prevention study among men who have sex with men in the iPrEx study in Chiang Mai, Thailand. AIDS Care. 2013;25(8):961–967. doi: 10.1080/09540121.2012.748871.
    1. Tellalian D, Maznavi K, Bredeek UF, Hardy WD. Pre-exposure prophylaxis (PrEP) for HIV infection: results of a survey of HIV healthcare providers evaluating their knowledge, attitudes, and prescribing practices. AIDS Patient Care STDs. 2013;27(10):553–559. doi: 10.1089/apc.2013.0173.
    1. Tripathi A, Ogbuanu C, Monger M, Gibson JJ, Duffus WA. Preexposure prophylaxis for HIV infection: healthcare providers’ knowledge, perception, and willingness to adopt future implementation in the southern US. South Med J. 2012;105(4):199–206. doi: 10.1097/SMJ.0b013e31824f1a1b.
    1. Tripathi A, Whiteside YO, Duffus WA. Perceptions and attitudes about preexposure prophylaxis among seronegative partners and the potential of sexual disinhibition. South Med J. 2013;106(10):558–564. doi: 10.1097/SMJ.0000000000000010.
    1. Van der Elst EM, Mbogua J, Operario D, et al. High acceptability of HIV pre-exposure prophylaxis but challenges in adherence and use: qualitative insights from a phase I trial of intermittent and daily PrEP in at-risk populations in Kenya. AIDS Behav. 2012;17(6):2162–2172. doi: 10.1007/s10461-012-0317-8.
    1. van der Straten A, Stadler J, Montgomery E, et al. Women’s experiences with oral and vaginal pre-exposure prophylaxis: the VOICE-C qualitative study in Johannesburg, South Africa. PLoS ONE. 2014;9(2):e89118. doi: 10.1371/journal.pone.0089118.
    1. Vernazza PL, Graf I, Sonnenberg-Schwan U, Geit M, Meurer A. Preexposure prophylaxis and timed intercourse for HIV-discordant couples willing to conceive a child. AIDS. 2011;25(16):2005–2008. doi: 10.1097/QAD.0b013e32834a36d0.
    1. Wagner GJ, Goggin K, Mindry D, et al. Correlates of use of timed unprotected intercourse to reduce horizontal transmission among Ugandan HIV clients with fertility intentions. AIDS Behav. 2015;19(6):1078–1088. doi: 10.1007/s10461-014-0906-9.
    1. Wamuti B, Odoyo J, Rono B, Cohen C, Bukusi E. Comparison of adherence with pre-exposure prophylaxis among HIV-1-negative clinical trial participants in serodiscordant relationships in Kisumu before and after release of the trial results. Paper presented at: 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Kuala Lumpur, 2013 [Oral Abstract-WEAC0105].
    1. Ware NC, Wyatt MA, Haberer JE, et al. Whatʼs love got to do with it? explaining adherence to oral antiretroviral pre-exposure prophylaxis for HIV-serodiscordant couples. J Acquir Immune Defic Syndr. 2012;59(5):463–468. doi: 10.1097/QAI.0b013e31824a060b.
    1. Weathers N, Nwagwu G. Perceptions of HIV pre-exposure chemoprophylaxis in high-risk men. Commun Nurs Res. 2013;46:268.
    1. Weber S, Waldura J, Cohan D. Safer conception options for HIV serodiscordant couples in the United States: experience of the National Perinatal HIV Hotline and Clinicians’ Network. Paper presented at: Journal of the International AIDS Society. Mexico, 2012.
    1. Wheelock A, Eisingerich AB, Ananworanich J, et al. Are Thai MSM willing to take PrEP for HIV prevention? An analysis of attitudes, preferences and acceptance. PLoS ONE. 2013;8(1):e54288. doi: 10.1371/journal.pone.0054288.
    1. Wheelock A, Eisingerich AB, Gomez GB, Gray E, Dybul MR, Piot P. Views of policymakers, healthcare workers and NGOs on HIV pre-exposure prophylaxis (PrEP): a multinational qualitative study. BMJ Open. 2012;2(4):e001234. doi: 10.1136/bmjopen-2012-001234.
    1. Whetham J, Taylor S, Charlwood L, et al. Pre-exposure prophylaxis for conception (PrEP-C) as a risk reduction strategy in HIV-positive men and HIV-negative women in the UK. AIDS Care. 2014;26(3):332–336. doi: 10.1080/09540121.2013.819406.
    1. White JM, Mimiaga MJ, Krakower DS, Mayer KH. Evolution of Massachusetts physician attitudes, knowledge, and experience regarding the use of antiretrovirals for HIV prevention. AIDS Patient Care STDS. 2012;26(7):395–405.
    1. Whiteside YO, Harris T, Scanlon C, Clarkson S, Duffus W. Self-perceived risk of HIV infection and attitudes about preexposure prophylaxis among sexually transmitted disease clinic attendees in South Carolina. AIDS Patient Care STDs. 2011;25(6):365–370. doi: 10.1089/apc.2010.0224.
    1. Wingood GM, Dunkle K, Camp C, et al. Racial differences and correlates of potential adoption of preexposure prophylaxis: results of a national survey. J Acquir Immune Defic Syndr. 2013;63(Suppl 1):S95–S101. doi: 10.1097/QAI.0b013e3182920126.
    1. Wong C, Parker C, Ahmed K, et al. Participant motivation for enrolling and continuing in the FEM-PrEP HIV prevention clinical trial. Paper presented at: International AIDS Society (IAS) 7th Conference on HIV Pathogenesis, Treatment and Prevention. Kuala Lumpur, 2013.
    1. Yang D, Chariyalertsak C, Wongthanee A, et al. Acceptability of pre-exposure prophylaxis among men who have sex with men and transgender women in northern Thailand. PLoS ONE. 2013;8(10):e76650. doi: 10.1371/journal.pone.0076650.
    1. Ye L, Wei S, Zou Y, et al. HIV pre-exposure prophylaxis interest among female sex workers in Guangxi, China. PLoS ONE. 2014;9(1):e86200. doi: 10.1371/journal.pone.0086200.
    1. Young I, Flowers P, McDaid LM. Barriers to uptake and use of pre-exposure prophylaxis (PrEP) among communities most affected by HIV in the UK: findings from a qualitative study in Scotland. BMJ Open. 2014;4(11):e005717. doi: 10.1136/bmjopen-2014-005717.
    1. Zhao Z, Sun Y, Xue Q, et al. [Acceptability of pre-exposure prophylaxis among female sex workers in Xinjiang] Zhejiang Da Xue Xue Bao Yi Xue Ban [J Zhejiang Univ, Med Sci] 2011;40(3):281–285.
    1. Zhong X, Zhong XN, Peng B, et al. Attitude on pre-exposure prophylaxis (PrEP) among drug users from high-risk population of aids in western China. Acad J Second Military Med Univ. 2012;33(4):374–379.
    1. Carlo Hojilla J, Koester KA, Cohen SE, et al. Sexual behavior, risk compensation, and HIV prevention strategies among participants in the San Francisco PrEP demonstration project: a qualitative analysis of counseling notes. AIDS Behav. 2015;20(7):1461–1469. doi: 10.1007/s10461-015-1055-5.
    1. Koester KA, Amico KR, Liu A, et al. Sex on PrEP: qualitative findings from the iPrEx open label extension (OLE) in the US. Paper presented at: 20th International AIDS Conference. Melbourne, 2014 [Abstract no. TUAC0102].
    1. UNAIDS, WHO, Wits. Sex workers’ hopes and fears for HIV pre-exposure prophylaxis: Recommendations from a discussion meeting 2013.
    1. NSWP. Global consultation: PrEP and early treatment as HIV prevention strategies: Sex workers community experiences and perspectives. 2014.
    1. INPUD and UNAIDS consultation on PrEP with people who inject drugs: Meeting report. Chisinau, 2014.
    1. Henderson M. Values and preferences of people who inject drugs, and views of experts, activists and service providers: HIV prevention, harm reduction and related issues. 2014.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren